MPN Clinical Trials

Clinical trials are an important step in the process of discovering new treatments for MPNs. The decision to participate in a clinical trial is one you should carefully consider. It is important to discuss clinical trial participation with your family and your physician. We've compiled a FAQ to assist patients who are considering participating in a clinical trial.

The MPN Research Foundation has complied a list of trials, some of which are currently recruiting patients:

If you are a company or investigator who is running a trial and you need to make a change to the listing for your trial contact our office at 312-683-7243 or by sending an email.

Find a Clinical Trial

Click the boxes below to filter clinical trials by disease type.

All
Myelofibrosis (MF)
Essential Thrombocythemia (ET)
Polycythemia Vera (PV)
MF

PF-04449913

PF-04449913 Single-Agent In Patients With Myelofibrosis Previously Treated With a Janus Kinase Inhibitor

Pfizer Clinical Trial Call Center: 1-800-718-1021 or contact us here

MF

Alisertib (MLN8237)

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), A Novel Inhibitor of Aurora Kinases, in Adult Patients with Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post-Polycythemic Myelofibrosis)

For more information about this study please contact us at: 312.472.123 or at nmdti@northwestern.edu

MF

Momelotinib

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

For more information, email momelotinib.studies@gilead.com

Full details available here.

MF

Ruxolitinib with Allogeneic Hematopoeitic Cell Transplantation

Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis.

Contact: Sara Duffey, Clinical Research and Education Specialist , Robert H. Lurie Comprehensive Cancer Center at 312.695.1102 or cancertrials@northwestern.edu

MF

P1101

This pilot phase II trial studies P1101 (polyethyleneglycol [PEG]-proline-interferon alpha-2b) in treating patients with early myelofibrosis. PEG-proline-interferon alpha-2b is a substance that can improve the body's natural response and may slow the growth of early myelofibrosis. More information available here: http://www.mpnresearchfoundation.org/PharmaEssentia-Corp.

Contact: Allison Rosenthal at Rosenthal.Allison@mayo.edu

MF

PRM-151

A Phase 2, Prospective Study of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)

More information is available at http://www.promoteclinicaltrials.com/ or please contact: promote@promedior.com.

MF

Ruxolitinib & SCT

Exploring the potential of dual kinase JAK1/2 inhibitor Ruxolitinib (INC424) with reduced intensity allogenic hematopoeitic stem cell transplantation in patients with myelofibrosis (MPD-RC #114)

Contact: Jill Kleczko at jill.kleczko@mssm.edu,

Vikas Gupta at 416-946-4521,

Adam Mead at adam.mead@imm.ox.ac.uk OR 44-0-1865-222325, or

John Mascarenhas at john.mascarenhas@mssm.edu

MF

Ruxolitinib & LDE225

A Phase1b/11 Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Contact: Novartis at 41-61-3241111

MF

Ruxolitinib & Panobinostst

Panobinostat and Ruxolitinib in myelofibrosis (Prime Study) - Phase I/II study of combination oral JAK2 tyrosine kinase inhibotor (JAK2-TKI) and histone deacetylase inhibitor (HDACI) therapy in patients with myelofibrosis

Contact: Jill Kleczko at jill.kleczko@mssm.edu or

John Mascarenhas at john.mascarenhas@mssm.edu

MF

Pomalidomide

Study of Pomalidomide in Persons with Myelofibrosis (RESUME)

Contact: Mary Bartlett at 913-266-0513 or mbartlett@celgene.com

Alyce Kay at 913-266-0369 or akay@celgene.com

MF

* LCL-161

Phase 2 LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Contact: Naveen Pemmaraju, MD at 713-792-4956

MF

Oral Arsenic

Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults with Myelofibrosis

Contact: Roswell Park Cancer Center Institute at 877-275-7724 or askrpci@rosewellpark.org

MF

* NS-018

Safety and Tolerability Study of Oral NS-018 in Patients with Myelofibrosis (MF) previously treated with a Janus Kinase Inhibitor,

(https://clinicaltrials.gov/ct2/show/NCT01423851For more information, contact Tomonori Uno of NS Pharma at: uno@nspharma.com

MF

Momelotinib (formerly CYT387)

Momelotinib Versus Ruxolitinib in Patients with Myelofibrosis

For more information, email momelotinib.studies@gilead.com or click here.

MF

INC424

INC424 for Patients with Myelofibrosis (JUMP)

Contact: Novartis Pharmaceuticals at +1-862-778-8300

MF

Ruxolitinib & Pracinostat

Evaluation of Ruxolitinib & Pracinostat Combination as a therapy for Patients with Myelofibrosis

Contact: Srdan Verstovsek, MD, PhD at 713-745-3429

MF

Pegasys

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms (DALIAH)

Contact: Thomas S. Larsen at thomas.stauffer.larsen@ouh.regionsyddanmark.dk or

Sally Grant at sally.grant@ouh.regionsyddanmark.dk

MF

TAK-901

A Phase 1 Dose Escalation Study of TAK-901 in Subjects with Advanced Hematological Malignancies

Contact: Millennium Medical or Drug Info Center at 877-674-3784 OR medical@mlnm.com

MF

Sotatercept (ACE-011)

Phase II, open-label study of sotatercept (ACE-011) in subjects with MF & significant anemia

Contact: Srdan Verstovsek, MD, PhD, at 713-745-3429

MF

Correlative Bio-Marker Study

Correlative Biomarker Study in Patients with Myeloproliferative Disorders

Contact: Rona S. Weinberg, PhD at 212-570-3412 OR rweinberg@nybloodcenter.org

Ronald Hoffman, MD at 212-241-2297 OR ronald.hoffman@mssm.edu

MF

Research Tissue Bank

Study allows for the preservation and storage of a small portion of tissues to be used for the study of MPDs.

Contact: Rona S. Weinberg, PhD at 212-570-3412 OR rweinberg@nybloodcenter.org

MF

SL-401

Phase I/II trial of SL-401 in patients with advanced, high risk MPNs, including MF, CMML, advanced systemic mastocytosis and HES/CEL

Contact: Srdan Verstovsek, MD, PhD at 713-745-3429

ETMFPV

Mirabegron

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Contact: Andrea Fuhrer, PhD at +41 31 389 92 63 OR andrea.fuhrer@sakk.ch

PV

Pegylated Interferon

AOP2014 in patients with Polycythemia Vera who previously participated in the PROUD-PV study

Contact: Michael Zoerer at michael.zoerer@aoporphan.com / 43+1+5037244-46 OR check clinicaltrials.gov

PV

* AOP2014 and Hydroxyurea

Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (PROUD-PV)

Contact: Michael Zoerer at 43+1+5037244-46 , OR michael.zoerer@aoporphan.com

ETMFPV

* Familial Study of MPDs

Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes

Contact: Dr. Josef Prchal at 801-581-4220 or Kim Hickman at 801-581-3707

ETPV

Pegasys

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Contact: Dr. Ronald Hoffman at ronald.hoffman@mssm.edu or 212-241-2296

ETPV

Open Label Study of Single Agent Oral RG7388

Sponsor: John Mascerenhas

Contact: John Mascarenhas, MD at (212) 241-3417 or john.mascarenhas@mssm.edu

Jill Kleczko at (212)241-0573 or jill.kleczko@mssm.edu

MF

Phase 2 LCL-161

For Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Sponsor: MD Anderson in collaboration with Novartis

Contact: Serge Verstovsek, MD at 713-792-7305 or sverstov@mdanderson.org

MF

Durvalumab

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis For more information contact the Study Coordinator at 312-695-1301 or cancertrials@northwestern.edu https://clinicaltrials.gov/ct2/show/NCT02871323?term=NCT02871323&rank=1
ETMFPV

CPI-0610

A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/ Myeloproliferative Neoplasms, and Myelofibrosis. For more information contact Debbie Johnson at debbie.johnson@constellationpharma.com
ETMFPV

PU-H71

The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies. For more information contact: John Gerecitano, MD, PhD 212-639-3748 OR Shanu Modi, MD 646-888-5243
MF

Nivolumab

Phase 2 study of Nivolumab in myelofibrosis. This drug uses a person's immune system to fight disease. Find out more: https://clinicaltrials.gov/ct2/show/NCT02421354?term=nivolumab+myelofibrosis&rank=1
MF

INCB050465 + Ruxolitinib

Phase 2 combination study in patients with Myelofibrosis. Find out more: https://clinicaltrials.gov/ct2/show/NCT02718300
MFMF

Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF (POMINC)

https://clinicaltrials.gov/ct2/show/NCT01644110?term=pomalidomide&recr=Open&rank=10
MF

Eltrombopag

Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF) https://clinicaltrials.gov/ct2/show/NCT01428635?term=eltrombopag&recr=Open&rank=10
MF

PIM447 + Ruxolitinib

Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis https://clinicaltrials.gov/ct2/show/NCT02370706?term=inc424&rank=10
ET

Ruxolitinib vs BAT in High Risk ET

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line https://clinicaltrials.gov/ct2/show/NCT02962388?term=xagrid&rank=15
MF

Ruxolitinib - Early Myelofibrosis

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. https://clinicaltrials.gov/ct2/show/NCT02598297?term=inc424&rank=12
MFPV

TGR-1202 + Ruxolitinib

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea https://clinicaltrials.gov/ct2/show/NCT02493530?term=hydroxyurea&recr=Open&rank=16
ETPV

Ruxolitinib - Ruxo-BEAT trial

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia (Ruxo-BEAT) https://clinicaltrials.gov/ct2/show/NCT02577926?term=hydroxyurea&recr=Open&rank=28
MF

Ruxolitinib + Thalidomide

A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis https://clinicaltrials.gov/ct2/show/NCT03069326?term=thalidomide+AND+ruxolitinib&rank=1
x

NEVER MISS AN UPDATE

Get free, timely information on living with an MPN.

Subscribe